A Phase I/II Open-Label Multicenter Single-Arm Study of FABLOx (Metronomic 5-Fluorouracil Plus nab-Paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin) in Patients with Metastatic Pancreatic Cancer

Vaibhav Sahai,M. Wasif Saif,Aparna Kalyan,Philip A. Philip,Caio M. Rocha-Lima,Allyson J. Ocean,Michael S. Ondovik,Diane M. Simeone,Sibabrata Banerjee,Rafia Bhore,Chrystal U. Louis,Vincent J. Picozzi

A Phase I/II Open-Label Multicenter Single-Arm Study of FABLOx (Metronomic 5-Fluorouracil Plus nab-Paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin) in Patients with Metastatic Pancreatic Cancer

2019

Vaibhav Sahai
M. Wasif Saif
Aparna Kalyan
Philip A. Philip
Caio M. Rocha-Lima
Allyson J. Ocean
Michael S. Ondovik
Diane M. Simeone
Sibabrata Banerjee
Rafia Bhore
Chrystal U. Louis
Vincent J. Picozzi

Abstract Purpose: To evaluate safety and preliminary efficacy of metronomic 5-fluorouracil plus nab-paclitaxel, bevacizumab, leucovorin, and oxaliplatin (FABLOx) in patients with newly diagnosed me...

Keywords:

Metastatic pancreatic cancer
Oncology
Nab-paclitaxel
Single Arm Study
Fluorouracil
Oxaliplatin
Bevacizumab
Medicine
Internal medicine
combination chemotherapy
phase i ii
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations